drugset / Trial / NCT03351231
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to investigate safety of experimental medication BMS-986242 and Nivolumab in patients with advanced cancers.
Timeline
- Start
- 2017-11-27
- Primary completion
- 2018-08-28
- Completion
- 2018-08-28
Outcome
Outcome not reported
Stopped: “Inability to meet protocol objectives”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-986242 | Unknown | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |